- 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
- 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
阿奇霉素序贯疗法治疗小儿支原体肺炎临床效果及安全性研究
阿奇霉素序贯疗法治疗小儿支原体肺炎临床效果及安全性研究
[摘要] 目的 研究分析阿奇霉素序贯疗法治疗小儿支原体肺炎的临床效果及其安全性。 方法 选取2011年11月~2013年11月在本院接受治疗的120例小儿支原体肺炎患儿,随机分为观察组和对照组,每组60例。观察组患儿采用阿奇霉素序贯疗法治疗,对照组单纯采用红霉素治疗,比较两组患儿的治疗效果、症状消失时间及不良反应情况。 结果 观察组总有效率为96.7%,显著高于对照组的78.3%,差异有统计学意义(P0.05);观察组退热、咳嗽及肺部湿??音消失时间均短于对照组,差异有统计学意义(P0.05);观察组不良反应发生率为3.33%,低于对照组的15.00%,差异有统计学意义(P0.05)。 结论 阿奇霉素序贯疗法治疗小儿支原体肺炎临床效果显著,不良反应少,值得临床推广应用。
[关键词] 阿奇霉素;序贯疗法;小儿支原体肺炎
[中图分类号] R725.6[文献标识码] A[文章编号] 1674-4721(2014)06(c)-0058-03
Clinical efficacy and safety study of azithromycin sequential therapy on Mycoplasma pneumonia in children
TANG Cai-e
Department of Paediatrics,Liyang Women and Children′s Health Service Centre of Jiangsu Province,Liyang 213300,China
[Abstract] Objective To explore and analyse the clinical efficacy and safety of azithromycin sequential therapy in the treatment of Mycoplasma pneumonia in children. Methods 120 cases of children patients with Mycoplasma pneumonia who were treated in our hospital from November 2011 to November 2013 were selected and randomly divided into observation group and control group,with 60 patients in each group.Patients in the observation group were received azithromycin sequential therapy,while the control group were received erythromycin only.Curative effect,symptom disappearing time and adverse events were compared between the two groups. Results Total effective rate in the observation group was 96.7%,significantly higher than 78.3% in the control group,the difference was significant (P0.05);disappearing time of fever,cough and pulmonary moist rales was shorter than that in the control group respectively,the difference was significant (P0.05);the incidence of adverse events in the observation group was 3.33%,lower than 15.00% in the control group,the difference was significant (P0.05). Conclusion Azithromycin sequential therapy for children patients with Mycoplasma pneumonia has a significant clinical effect and rare adverse events,which is worthy of clinical promotion and a
文档评论(0)